Open AccessRandomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
Author(s) -
K. Kian Ang,
Qiang Zhang,
David I. Rosenthal,
Phuc Félix NguyenTan,
Eric J. Sherman,
Randal S. Weber,
James M. Galvin,
James A. Bonner,
Jonathan Harris,
Adel K. ElNaggar,
Maura L. Gillison,
Richard C. Jordan,
André Konski,
Wade L. Thorstad,
Andy Trotti,
Jonathan J. Beitler,
Adam S. Garden,
William J. Spanos,
Sue S. Yom,
Rita Axelrod
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2013.53.5633
Subject(s) - cetuximab , medicine , common terminology criteria for adverse events , mucositis , rash , radiation therapy , oncology , cisplatin , head and neck cancer , nasopharyngeal carcinoma , chemotherapy , cancer , colorectal cancer
Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom